These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1039 related articles for article (PubMed ID: 24845869)
1. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease. Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869 [TBL] [Abstract][Full Text] [Related]
2. Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats. Bender TS; Migliore MM; Campbell RB; John Gatley S; Waszczak BL Neuroscience; 2015 Sep; 303():569-76. PubMed ID: 26166725 [TBL] [Abstract][Full Text] [Related]
3. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease. Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725 [TBL] [Abstract][Full Text] [Related]
4. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795 [TBL] [Abstract][Full Text] [Related]
5. Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway. Yue P; Gao L; Wang X; Ding X; Teng J Neurochem Res; 2017 May; 42(5):1366-1374. PubMed ID: 28247332 [TBL] [Abstract][Full Text] [Related]
6. Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease. Wang X; Cui G; Yang X; Zhang Z; Shi H; Zu J; Hua F; Shen X Brain Res Bull; 2014 Apr; 103():60-5. PubMed ID: 24583079 [TBL] [Abstract][Full Text] [Related]
7. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539 [TBL] [Abstract][Full Text] [Related]
8. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043 [TBL] [Abstract][Full Text] [Related]
9. Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson's Disease. Aly AE; Harmon BT; Padegimas L; Sesenoglu-Laird O; Cooper MJ; Waszczak BL Mol Neurobiol; 2019 Jan; 56(1):688-701. PubMed ID: 29779176 [TBL] [Abstract][Full Text] [Related]
10. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. Yasuhara T; Shingo T; Muraoka K; Kobayashi K; Takeuchi A; Yano A; Wenji Y; Kameda M; Matsui T; Miyoshi Y; Date I J Neurosurg; 2005 Jan; 102(1):80-9. PubMed ID: 15658100 [TBL] [Abstract][Full Text] [Related]
11. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Rosenblad C; Kirik D; Björklund A Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072 [TBL] [Abstract][Full Text] [Related]
12. GFR-α1 Expression in Substantia Nigra Increases Bilaterally Following Unilateral Striatal GDNF in Aged Rats and Attenuates Nigral Tyrosine Hydroxylase Loss Following 6-OHDA Nigrostriatal Lesion. Kasanga EA; Owens CL; Cantu MA; Richard AD; Davis RW; McDivitt LM; Blancher B; Pruett BS; Tan C; Gajewski A; Manfredsson FP; Nejtek VA; Salvatore MF ACS Chem Neurosci; 2019 Oct; 10(10):4237-4249. PubMed ID: 31538765 [TBL] [Abstract][Full Text] [Related]
13. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats. Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829 [TBL] [Abstract][Full Text] [Related]
14. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats. Lu X; Hagg T J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855 [TBL] [Abstract][Full Text] [Related]
15. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166 [TBL] [Abstract][Full Text] [Related]
16. Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease. Zhu G; Wang X; Chen Y; Yang S; Cheng H; Wang N; Li Q Planta Med; 2010 Nov; 76(16):1820-6. PubMed ID: 20509103 [TBL] [Abstract][Full Text] [Related]
18. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445 [TBL] [Abstract][Full Text] [Related]
20. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action. Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK eNeuro; 2017; 4(1):. PubMed ID: 28303260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]